Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Adaptive radiotherapy study for head and neck cancer withdrawn before starting

NCT ID NCT03953352

Knowledge-focused Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to test whether automatic software could accurately outline tumors and healthy organs on daily CT scans during radiation therapy for head and neck cancer. The goal was to save time and improve precision compared to manual contouring. However, the study was withdrawn before enrolling any participants, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Helical intensity-modulated radiotherapy (IMRT)

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Expected to start

Aug 2019

An estimate. Start dates often move.

Expected to finish

Jan 2021

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years old 2. Patient with histologically proven locally advanced head and neck cancer (Oropharynx, hypopharynx, larynx, nasopharynx, oral cavity, sinuses, nasal cavities, ethmoid sinus, cavum, salivary glands) 3. Cancer with nodal involvement (at least T3 or involved node \>2 cm) 4. Eastern Cooperative Oncology Group performance status 0 or 1 5. No previous curative treatment for head and neck cancer (surgery and/or radiotherapy and/or chemotherapy) 6. Indication of exclusive radiotherapy (+/- chemotherapy) validated in multidisciplinary meeting 7. Patient affiliated to the french social security system. 8. Patient must provide written informed consent prior to inclusion in the study and any study-specific procedure. Exclusion Criteria: 1. Patient with metastatic cancer 2. Eastern Cooperative Oncology Group performance status ≥ 2 (due to comorbidities) 3. Patient with recurrent disease 4. Patient who required urgent surgical treatment 5. Contraindications to radiotherapy 6. History of cancer within 5 years 7. Patient already included in another therapeutic trial 8. Pregnant or breastfeeding women 9. Any psychological, familial, geographical or sociological condition potentially preventing the medical follow-up and/or study procedures 10. Patient protected by law

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Head and neck cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Head and neck cancer

Contacts and locations

Locations

  • Institut Universitaire Du Cancer Toulouse - Oncopole (Iuct-O)

    Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.